Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2013 1
2018 2
2019 6
2020 7
2021 6
2022 7
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
Chen TW, Hsiao W, Dai MS, Lin CH, Chang DY, Chen IC, Wang MY, Chang SH, Huang SM, Cheng AL, Wu KW, Tan KT, Lu YS. Chen TW, et al. Among authors: tan kt. Breast Cancer Res Treat. 2023 Oct;201(3):377-385. doi: 10.1007/s10549-023-06967-3. Epub 2023 Jun 21. Breast Cancer Res Treat. 2023. PMID: 37344660 Free PMC article.
PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy.
Tan KT, Yeh CN, Chang YC, Cheng JH, Fang WL, Yeh YC, Wang YC, Hsu DS, Wu CE, Lai JI, Chang PM, Chen MH, Lu ML, Chen SJ, Chao Y, Hsiao M, Chen MH. Tan KT, et al. J Immunother Cancer. 2020 Mar;8(1):e000485. doi: 10.1136/jitc-2019-000485. J Immunother Cancer. 2020. PMID: 32238472 Free PMC article.
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors.
Choo JRE, Jan YH, Ow SGW, Wong A, Lee MX, Ngoi N, Yadav K, Lim JSJ, Lim SE, Chan CW, Hartman M, Tang SW, Goh BC, Tan HL, Chong WQ, Yvonne ALE, Chan GHJ, Chen SJ, Tan KT, Lee SC. Choo JRE, et al. Among authors: tan kt. Target Oncol. 2022 May;17(3):355-368. doi: 10.1007/s11523-022-00886-x. Epub 2022 Jun 14. Target Oncol. 2022. PMID: 35699834 Free PMC article.
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.
Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, Huang CJ, Chen SC, Shan YS, Chao Y, Huang YH, Lee IC, Lee PC, Su YY, Chen SJ, Yeh CN, Chen LT, Chen MH. Chiang NJ, et al. Among authors: tan kt. Clin Cancer Res. 2022 Oct 3;28(19):4248-4257. doi: 10.1158/1078-0432.CCR-22-1152. Clin Cancer Res. 2022. PMID: 35849151 Free PMC article. Clinical Trial.
31 results